Trials / Completed
CompletedNCT00547534
Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma
Pilot Study of Bortezomib, Bendamustine and Rituximab for Patients With Relapsed or Refractory, Indolent or Mantle Cell Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- University of Rochester · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate how non-Hodgkin's lymphoma that has not responded to, or that has returned after standard treatment, responds to bortezomib, rituximab and bendamustine, and also to see what effects this drug combination have on this cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bortezomib | 1.3 mg/m\^2 on days 1, 4, 8, 11 |
| DRUG | bendamustine | 90 mg/m\^2 days 1 and 4 |
| DRUG | rituximab | 375 mg/m\^2 day 1 |
Timeline
- Start date
- 2007-10-01
- Primary completion
- 2009-06-01
- Completion
- 2009-10-01
- First posted
- 2007-10-22
- Last updated
- 2015-08-06
- Results posted
- 2011-06-06
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00547534. Inclusion in this directory is not an endorsement.